Brokerages Set Oracle Co. (NYSE:ORCL) Price Target at $57.60

Share on StockTwits

Shares of Oracle Co. (NYSE:ORCL) have earned an average rating of “Hold” from the thirty analysts that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a sell rating, seventeen have given a hold rating and nine have given a buy rating to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $57.60.

ORCL has been the topic of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “hold” rating on shares of Oracle in a research report on Thursday, September 12th. JPMorgan Chase & Co. set a $56.00 target price on shares of Oracle and gave the company a “neutral” rating in a research report on Thursday, September 12th. Argus reissued a “buy” rating on shares of Oracle in a research report on Friday, September 13th. Wedbush reissued a “neutral” rating and set a $55.00 price target on shares of Oracle in a research report on Friday, September 13th. Finally, Macquarie reissued a “hold” rating on shares of Oracle in a research report on Thursday, September 12th.

NYSE ORCL traded down $0.12 during trading hours on Monday, reaching $56.09. The company had a trading volume of 9,055,406 shares, compared to its average volume of 13,347,093. The stock has a 50-day moving average of $55.07 and a 200 day moving average of $54.85. Oracle has a 1-year low of $42.40 and a 1-year high of $60.50. The company has a current ratio of 2.25, a quick ratio of 2.25 and a debt-to-equity ratio of 2.67. The stock has a market capitalization of $185.23 billion, a P/E ratio of 17.75, a price-to-earnings-growth ratio of 1.67 and a beta of 1.16.

Oracle (NYSE:ORCL) last posted its earnings results on Wednesday, September 11th. The enterprise software provider reported $0.81 EPS for the quarter, beating the Zacks’ consensus estimate of $0.72 by $0.09. Oracle had a net margin of 27.71% and a return on equity of 48.85%. The company had revenue of $9.22 billion for the quarter, compared to analysts’ expectations of $9.29 billion. During the same quarter in the prior year, the company posted $0.71 earnings per share. Oracle’s revenue for the quarter was up .2% compared to the same quarter last year. As a group, sell-side analysts predict that Oracle will post 3.47 EPS for the current year.

Oracle announced that its board has authorized a share buyback program on Wednesday, September 11th that permits the company to buyback $15.00 billion in outstanding shares. This buyback authorization permits the enterprise software provider to purchase up to 8.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board believes its shares are undervalued.

The company also recently announced a quarterly dividend, which was paid on Thursday, October 24th. Investors of record on Thursday, October 10th were paid a dividend of $0.24 per share. The ex-dividend date was Wednesday, October 9th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.71%. Oracle’s payout ratio is 30.38%.

In related news, Director Jeffrey Berg sold 9,550 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $56.59, for a total transaction of $540,434.50. Also, CEO Mark V. Hurd sold 787,500 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $51.80, for a total transaction of $40,792,500.00. Following the sale, the chief executive officer now owns 1,038,755 shares in the company, valued at $53,807,509. The disclosure for this sale can be found here. Insiders have sold 859,336 shares of company stock worth $44,753,591 over the last 90 days. Insiders own 36.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ORCL. Nuveen Asset Management LLC increased its stake in shares of Oracle by 6,437.0% during the second quarter. Nuveen Asset Management LLC now owns 10,144,910 shares of the enterprise software provider’s stock worth $577,955,000 after buying an additional 9,989,718 shares during the period. Longview Partners Guernsey LTD increased its stake in shares of Oracle by 16.9% during the second quarter. Longview Partners Guernsey LTD now owns 22,243,759 shares of the enterprise software provider’s stock worth $1,267,227,000 after buying an additional 3,220,296 shares during the period. Renaissance Technologies LLC increased its stake in shares of Oracle by 2,952.4% during the second quarter. Renaissance Technologies LLC now owns 2,970,032 shares of the enterprise software provider’s stock worth $169,203,000 after buying an additional 2,872,732 shares during the period. LSV Asset Management increased its stake in shares of Oracle by 37.8% during the second quarter. LSV Asset Management now owns 8,335,383 shares of the enterprise software provider’s stock worth $474,866,000 after buying an additional 2,286,600 shares during the period. Finally, Beutel Goodman & Co Ltd. increased its stake in shares of Oracle by 62.5% during the second quarter. Beutel Goodman & Co Ltd. now owns 5,578,093 shares of the enterprise software provider’s stock worth $231,296,000 after buying an additional 2,146,084 shares during the period. Hedge funds and other institutional investors own 53.81% of the company’s stock.

Oracle Company Profile

Oracle Corporation develops, manufactures, markets, sells, hosts, and supports application, platform, and infrastructure solutions for information technology (IT) environments worldwide. The company provides services in three primary layers of the cloud: Software as a Service, Platform as a Service, and Infrastructure as a Service.

See Also: Quiet Period Expirations Explained

Analyst Recommendations for Oracle (NYSE:ORCL)

Receive News & Ratings for Oracle Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oracle and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.